Abstract
AbstractUnlike other areas of medicine, such as cardiology and diabetology, urology has often been slow to embrace strategies for risk reduction. Currently, urologists prefer to treat the disease at the stage they encounter it, rather than approaching the problem with a preventative frame of mind. However, a recent publication evaluating the effect of dutasteride on prostate cancer calls this view into question. The current lifetime risk of prostate cancer in the USA is estimated at 16.7 per cent. As the disease is both extremely common and generally slow to progress, potentially it provides a prime target for chemoprevention.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call